DDInter1642 DDInter146
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill cancer cells, and are infused back into the patient. Each dose of axicabtagene ciloleucel represent the patient's genetically modified T-cells. The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR can produce cytokines that efficiently kill leukemic cells _in vitro_. Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.
Axicabtagene ciloleucel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Axicabtagene ciloleucel {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Axicabtagene ciloleucel {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Axicabtagene ciloleucel may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Axicabtagene ciloleucel may lead to a major life threatening interaction when taken with Tofacitinib
Axicabtagene ciloleucel may lead to a major life threatening interaction when taken with Upadacitinib